A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
- Resource Type
- Journal
- Source
JOURNAL OF CLINICAL ONCOLOGY ; MAY 20 2017, 35 5p. Supplement: 15- Subject
- Language
- English
- ISSN
- 15277755